Back to Articles
GeneralBusiness Today

Biocon’s breast cancer biosimilar gets a positive EMA opinion; closer to launching therapy in EU

Pertuzumab biosimilar Pebrilzo gets positive EMA committee opinion, taking Biocon Biologics closer to a European launch.

Attribution

This digest is published with acknowledgment to Business Today. For the complete analysis, headnotes, and citations, please refer to the source.

Read on Business Today

More Articles